Phio Pharmaceuticals (PHIO)Director bought ~$5.2K

~$5.2K

Approx. value · 5,000 sh @ $1.03

37K

Holds after · shares reported

Traded

Sep 28, 2026

Filed

Sep 30, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 18, 2026InsiderCEO purchased ~$11K of PHIO shares in the open market
3. Aug 19, 2026Insider · Largest insider buy since 2013Director purchased ~$17K of PHIO shares in the open market
4. Sep 15, 2026Insider · 13 days before an 8-KDirector purchased ~$12K of PHIO shares in the open market
5. Sep 22, 2026Insider · 6 days before an 8-KCEO purchased ~$2.1K of PHIO shares in the open market
6. Sep 24, 2026Insider · 4 days before an 8-KDirector purchased ~$6.6K of PHIO shares in the open market
7. Sep 28, 2026 · this disclosureInsider · 3 insiders in a week, 2nd time since 2013Director purchased ~$5.2K of PHIO shares in the open market

What came next

1. Sep 28, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“Phio Pharmaceuticals Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders via live webcast (the “Annual Meeting”) on September 28, 2026.”
2. Sep 29, 2026InsiderDirector purchased ~$5.2K of PHIO shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Phio Pharmaceuticals

For Phio Pharmaceuticals, OQRO holds 7 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PHIO page.

Other recent filings by Ronald Todd Plott, Director

• SEC Form 4 at Phio Pharmaceuticals (PHIO)Sep 30, 2026
• SEC Form 4 at Phio Pharmaceuticals (PHIO)Aug 20, 2026

The full history of Ronald Todd Plott, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Phio Pharmaceuticals

• SEC Form 4Sep 30, 2026
• SEC Form 4Sep 25, 2026
• SEC Form 4Sep 23, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Aug 20, 2026
• SEC Form 4Aug 19, 2026

Everything OQRO holds on this company is on its PHIO page.